Journal of Diabetes and Endocrine Practice

CASE REPORT
Year
: 2021  |  Volume : 4  |  Issue : 4  |  Page : 206--209

Subacute thyroiditis following COVID19 vaccine: Report of four cases


Sara El Ghandour1, Nisrine Al Ghazal2 
1 Department of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences; Department of Endocrinology, Mediclinic Parkview Hospital, Dubai, United Arab Emirates
2 Department of Endocrinology, Mediclinic Dubai Mall, Dubai, United Arab Emirates

Correspondence Address:
Sara El Ghandour
Department of Endocrinology, Mediclinic Parkview Hospital, Dubai
United Arab Emirates

An increase in the incidence of subacute thyroiditis (SAT) following the COVID-19 vaccine. The aim of this report is to shed the light on different presentations of SAT postCOVID-19 vaccine while reviewing the link between the vaccine and subsequent thyroid inflammation. We present the case of a middle-aged man who presented symptoms of SAT 1-week postvaccine. He achieved euthyroidism 6 weeks later. We also present the case of a middle-aged woman with less severe symptoms of SAT 4 weeks after the vaccine. She is in the hypothyroid phase 11 weeks later. A 37-year-old male developed severe symptoms 2 weeks after the first dose and is still hyperthyroid 5 weeks later. A 36-year-old woman presented with silent SAT 3 weeks after the first dose. Cases of SAT following SARS-Cov-2 are now reported increasingly. COVID-19 can cause thyroiditis via direct cell, or alternatively though immune destruction of the thyroid in genetically susceptible individuals. Similarly, the vaccine can promote inflammation through the same mechanisms. Indeed, there is a postulated cross-reactivity between the spike protein and thyroid antigens. More-so, there is the studied vaccine adjuvant effect on the endocrine system, namely the thyroid in this case. Cases of SAT postCOVID-19 vaccines are increasingly reported. Theories are similar to COVID19-induced thyroiditis but also other mechanisms are uniquely mediated by vaccines. A low threshold should be set to diagnose SAT in patients with one or more hyperthyroid symptoms presenting 1–8 weeks postCOVID-19 vaccine.


How to cite this article:
El Ghandour S, Al Ghazal N. Subacute thyroiditis following COVID19 vaccine: Report of four cases.J Diabetes Endocr Pract 2021;4:206-209


How to cite this URL:
El Ghandour S, Al Ghazal N. Subacute thyroiditis following COVID19 vaccine: Report of four cases. J Diabetes Endocr Pract [serial online] 2021 [cited 2024 Mar 29 ];4:206-209
Available from: https://www.jdeponline.com/article.asp?issn=2772-7653;year=2021;volume=4;issue=4;spage=206;epage=209;aulast=El;type=0